PureIMS

Very proud to announce PureIMS’s deal with globally operating personalized medicine company Fagron on our Cyclops® inhaled antibiotic CF product. Read the OINDP press release at: https://lnkd.in/eXutU8sJ In case of any questions, contact us at info@pureims.com #Fagron #PureIMS #deal #partnership #Netherlands #Cyclops #personlizedmedicine #antibiotics #cysticfibrosis

I’ll be attending CPHI, looking to connect with companies interested in in-licensing PureIMS’s innovative inhaled therapies (www.pureims.com/products): > Levodopa Cyclops®: Tackling off episodes in Parkinson's Disease > Colistin Cyclops®: Proven antibiotic therapy for Cystic Fibrosis > Epinephrine Cyclops®: Preventing anaphylactic shocks in allergy care or .... companies seeking what could be the best dry powder inhaler for their own drug delivery needs. Let me know when you're there, would appreciate talking on the above topics, and let’s explore potential collaborations. #CPHI #inhaleddrugdelivery #dpi #levodopa #parkinsonsdisease #antibiotics #cysticfibrosis #epinephrine #allergy #partnering #codevelopment #Cyclops #pureims

Jaap Wieling will present our latest poster (#708) on Levodopa Cyclops® during the ‘International Congress of Parkinson’s Disease and Movement Disorders’ in Philadelphia on Sunday the 29th of September 2024 (Exhibit Hall A). For those not visiting the conference: https://lnkd.in/euzKMafq Highlights: - Levodopa Cyclops® is safe and very well tolerated (no cough). - Results enable abbreviated registration routes with a limited – PK-only – clinical program in healthy volunteers. - Levodopa Cyclops® is very easy to use and systemic absorption is fast, so it will be a valuable asset to offer fast and reliable relief of debilitating OFF episodes. #Parkinsonsdisease #Levodopa #Cyclops #licensing #inhalation #PureIMS

Jaap Wieling will present our latest poster (#708) on Levodopa Cyclops® during the ‘International Congress of Parkinson’s Disease and Movement Disorders’ in Philadelphia on Sunday the 29th of September 2024 (Exhibit Hall A). For those not visiting the conference: https://lnkd.in/euzKMafq Highlights: - Levodopa Cyclops® is safe and very well tolerated (no cough). - Results enable abbreviated registration routes with a limited – PK-only – clinical program in healthy volunteers. - Levodopa Cyclops® is very easy to use and systemic absorption is fast, so it will be a valuable asset to offer fast and reliable relief of debilitating OFF episodes. #Parkinsonsdisease #Levodopa #Cyclops #licensing #inhalation #PureIMS

Dr. Jaap Wieling, CEO of PureIMS, captivated an engaged audience during his presentation"Next Generation Patient-Centric Cyclops® Inhalers for Multidose Applications".

This Sunday, September 8 is Worldwide Cystic Fibrosis Day   Since the FDA approved Kalydeco® in 2012, CFTR modulators show to greatly contribute to CF treatment. Still, other medicinal therapies (e.g. antibiotics) remain necessary to prevent or treat Pseudomonas aeruginosa lung infections. Colistin, when inhaled, shows very limited systemic exposure, is effective in treating these infections and is very insensitive to antimicrobial resistance. Colistin Cyclops®, developed by PureIMS, is utilizing the Cyclops® dry powder inhaler. This treatment requires less than a minute for administration and is very well tolerated by patients, causing minimal cough. Colistin Cyclops® is currently in development for the treatment of P. aeruginosa infections in cystic fibrosis (CF) and non-CF bronchiectasis.   For more information, check: www.pureims.com/products #CysticFibrosis #Bronchiectasis #Colistin #Cyclops #inhalation #dpi #PureIMS #partnering

Will you be visiting ERS in Vienna next week? Please inform Frank Lambert, so we can meet up.

September is shaping up to be a busy month for PureIMS!   With a diverse array of interesting conferences across Europe and beyond, our experts are seizing the opportunity to discuss the extensive capabilities of Cyclops® for inhaled drug delivery. This encompasses not only repurposed drugs, new chemical entities (NCEs), and new biological agents (NBAs), but also includes mucosal vaccination programs and diagnostics, among other strategies. Do register for one or more of the conferences below and be sure to contact Frank Lambert or Jaap Wieling in advance so we can set aside some dedicated time for you. - Sep 4-5      IPAC-RS Workshop Inhaled Biologics –  Washington DC* - Sep 7-11    European Respiratory Society (ERS) Congress – Vienna - Sep 11-13  Exploring the Future of Inhalation Drug Delivery – Parma* - Sep 19-20  Annual Inhalation and Respiratory Drug Delivery Conference – Berlin* - Sep 26-27  Annual Inhaled and Nasal Biologics/DNA Forum – Cambridge UK* - Sep 28-30  Int'l Congress of PD and Movement Disorders – Philadelphia (* PureIMS will be lecturing at these conferences.) #PureIMS #Cyclops #Inhaleddrugdelivery #conference #drypowderinhaler #respiratory #partnering

Great news! Congratulations to Amneal for their novel longer acting levodopa product, and to the Parkinson's community! While this new medication offers an additional 30 minutes of "on time" per day, there remains a significant unmet medical need for treating the persistent off episodes that 50 to 70% of patients will inevitably experience on a daily basis. PureIMS in the Netherlands is offering its late-stage Cyclops®-inhaled levodopa program for in-licensing, designed specifically to better address these challenging off episodes. Reach out to Frank Lambert if you’re interested in learning more. www.pureims.com/products #Parkinsonsdisease #Levodopa #Inhaleddrugdelivery #Cyclops #partnering

Very interesting contribution on inhaled levodopa with a Parkinson’s-patient-centric Dry-powder inhaler by Paul Hagedoorn, University of Groningen. This Cyclops-based levodopa inhalation product is very close to market introduction.